Skip to main content
All Posts By

laurabbook@gmail.com

Onc Live
ResearchTreatments

FDA Approval Sought for Amivantamab Plus Chemo in EGFR Exon 20 Insertion+ NSCLC

*August 2023* A supplemental biologics license application (sBLA) seeking the expanded approval of amivantamab-vmjw (Rybrevant) in combination with carboplatin plus pemetrexed for use in the frontline treatment of patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations has been submitted to the FDA.1  …
laurabbook@gmail.com
September 29, 2023
Precision Oncology Connect
ResearchTreatments

Podcast: An Introduction to Molecular Testing

*July 2023* In this podcast, Dr Tracy Stockley, pathologist and geneticist, University Health Network, and Prof. David Hong, medical oncologist, MD Anderson, come together to provide an introduction to molecular testing. Listen as they discuss: Why identifying genetic alterations is so important How targeted therapies impact outcomes When to use molecular profiling…
laurabbook@gmail.com
September 29, 2023
Onc Live
ResearchTreatments

ADCs Offer Exciting Potential in Lung Cancer

*July 2023* Antibody-drug conjugates (ADC) represent one of the most exciting areas of ongoing development for the treatment of patients with non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), according to Karen Reckamp, MD, MS, during a presentation at the 24th Annual International Lung Cancer Congress®.1 “This is the…
laurabbook@gmail.com
September 29, 2023
ResearchTreatments

Phase 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy With and Without Lazertinib versus Chemotherapy Alone in Patients with EGFR+ NSCLC after Disease Progression on Osimertinib

*September 2023* RARITAN, N.J., Sept. 6, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the three-arm Phase 3 MARIPOSA-2 study evaluating RYBREVANT® (amivantamab-vmjw), a bispecific antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), given with and without lazertinib, an oral, third-generation…
laurabbook@gmail.com
September 29, 2023
Paul Stockhammer
ResearchTreatments

Clinician Spotlight: Paul Stockhammer, MD, PhD

*September 2023* This month we have the honor of featuring Paul Stockhammer, MD, PhD. As a third-year resident at Yale School of Medicine last year, Dr Stockhammer received the Distinguished Young Investigator Research Award at the 2022 EGFR Research Summit for his work entitles “Co-occurring Alterations in Multiple Tumor Suppressor…
laurabbook@gmail.com
September 29, 2023
journal of clinical oncology logo
ResearchTreatments

Zipalertinib in EGFR Exon 20–Mutant Non–Small-Cell Lung Cancer: Drug Development in a Rare but Crowded Setting

*July 2023* In the article that accompanies this editorial, Piotrowska et al3 attempt to fill that void with results from a phase I/II study of zipalertinib, an irreversible, oral EGFR TKI in patients with recurrent or metastatic NSCLC harboring EGFR ex20ins mutations. In preclinical models, zipalertinib demonstrated selective inhibition of EGFR ex20ins, with minimal activity…
laurabbook@gmail.com
September 29, 2023